Antibe Therapeutics Inc(Pre-Merger) ATBPF

Long history of Safety Concerns

[nozzpack]

In May 2014, the company announced that it had completed pre-clinical studies on ATB-346.^[7] 

In late June 2014, following approval from Health Canada, the company announced the first human dosing for Phase I of its human clinical trials.^[8] 

In mid-January 2015, the company announced that clinical trials for its ATB-346 were being suspended due to safety concerns; clinical trials were restarted in March 2015.


So, what you are now seeing, after 6 more years, are the same safety concerns.

Lets face it.
This ultimate solution to GI side effects has been on the go since 2009.

Yet, its progression through clinical trials has not moved a single step.

That is a huge red flag that is now showing up in many fake clinical trials of drugs that, with clever promotion , can still take in the sheeple who know not what they buy.

GLTA

This is a failed drug that will never get approved due to significant safety concerns 

[themagicbox]

Completely disagree.  ATB346 is still safer than ALL the other NSAIDs on the market in terms of LTEs. And still lowest SE overall compared to other NSAIDs. By your logic a drug like Tylenol would never get approved and yet it has.  There is no adverse even only an elevation to ALTs. Phase 2B LTE incidences were comparable to that observed with commonly prescribed NSAIDs (~4%) and

[WalkOverTheStrt]

snozz  Where are your facts, b/c they paused a trial and then restarted after review? Seems pretty weak when PH2 had same liver profile to acetaminophen use ... (side 38)  During the treatment period, only 1 out of 318 patients administered otenaproxesul had clinically significant, temporary liver enzyme elevations (“LTEs”) — this is a known “class effect” of NSAIDs • At the post

[nozzpack]

Once again , expectations for 346 data were have been thwarted  by significant acetaminophin percentages . This hydrogen sulphide releasing  discovery was made in 2009. After dozens of clinical trials since then, it remains a stranded drug that can it advance due to safety concerns. How much clearer do you want this failure to be stated,,

[HarveyTwoface]

Aaaah yes...We have all been scammed by Stauffer, Wallace, Nobel laureate & Co !! My God, let's rather listen to s**t for brains here!

[WalkOverTheStrt]

Harvey - it's fun to play with these trolls that state these safety concerns but won't counter points when presented with PH2 data... ive heard some dumb lines by trolls of late. One of them is the FDA wouldnt approve current NSDAIDs, other otc pain meds... lol it's too funny how dumb their logic is. 

[WalkOverTheStrt]

SNozzle - Your history of safety concerns is such bs it's clear your agenda... please feel free to read through the PH2 study results showing that you're full of bs / which you like to ignore... https://bpspubs.onlinelibrary.wiley.com/doi/10.1111/bph.14641 Cumulative data from the three clinical trials in which ATB-346 has been administered at 250 mg once daily for 10–14 days

[Danorrn]

It's clear the market doesn't share his concern.